564 related articles for article (PubMed ID: 29904950)
1. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Kattamis A; Aydinok Y; Taher A
Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
[TBL] [Abstract][Full Text] [Related]
2. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
3. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
Taher AT; Origa R; Perrotta S; Kouraklis A; Ruffo GB; Kattamis A; Goh AS; Huang V; Zia A; Herranz RM; Porter JB
Health Qual Life Outcomes; 2018 Nov; 16(1):216. PubMed ID: 30453981
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
6. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Shammo JM; Komrokji RS
Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
[TBL] [Abstract][Full Text] [Related]
7. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Gattermann N
Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
[TBL] [Abstract][Full Text] [Related]
9. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
10. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Angelucci E; Li J; Greenberg P; Wu D; Hou M; Montano Figueroa EH; Rodriguez MG; Dong X; Ghosh J; Izquierdo M; Garcia-Manero G;
Ann Intern Med; 2020 Apr; 172(8):513-522. PubMed ID: 32203980
[TBL] [Abstract][Full Text] [Related]
11. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.
Pinto VM; Balocco M; Quintino S; Bacigalupo L; Gianesin B; Rizzi M; Malagò R; De Franceschi L; Forni GL
Am J Hematol; 2018 Oct; 93(10):E338-E340. PubMed ID: 30033633
[No Abstract] [Full Text] [Related]
12. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
Escudero-Vilaplana V; Garcia-Gonzalez X; Osorio-Prendes S; Romero-Jimenez RM; Sanjurjo-Saez M
J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
[TBL] [Abstract][Full Text] [Related]
13. A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.
Wei Z; Yang G; Huang Y; Peng P; Long L; Long Y; Huang X; Zhou X; Lai Y; Liu R
Br J Haematol; 2020 Nov; 191(3):e81-e83. PubMed ID: 32945527
[No Abstract] [Full Text] [Related]
14. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
Cheng WY; Said Q; Hao Y; Xiao Y; Vekeman F; Bobbili P; Duh MS; Nandal S; Blinder M
Curr Med Res Opin; 2018 Nov; 34(11):1959-1966. PubMed ID: 29701080
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
Antmen B; Karakaş Z; Yeşilipek MA; Küpesiz OA; Şaşmaz İ; Uygun V; Kurtoğlu E; Oktay G; Aydogan G; Akın M; Salcioglu Z; Vergin C; Kazancı EG; Ünal S; Çalışkan Ü; Aral YZ; Türkkan E; Meral Güneş A; Tunç B; Gümrük F; Ayhan AC; Söker M; Koç A; Oymak Y; Ertem M; Timur Ç; Yıldırmak Y; İrken G; Apak H; Biner B; Eren TG; Işık Balcı Y; Koçak Ü; Karasu G; Akkaynak D; Patıroğlu T
Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449
[TBL] [Abstract][Full Text] [Related]
16. To chelate or not to chelate in MDS: That is the question!
Zeidan AM; Griffiths EA
Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
[TBL] [Abstract][Full Text] [Related]
17. Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Piciocchi A; Sargentini V; Cotugno F; Bontempi K; Beltrami G; Di Tucci AA; Riva M; Quaresmini G; Vallisa D; Finelli C; Borin L; Fazi P; Vignetti M; Angelucci E
Eur J Haematol; 2019 May; 102(5):442-443. PubMed ID: 30776156
[No Abstract] [Full Text] [Related]
18. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
19. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
Taher AT; Wali Y; Cruz MC; Charoenkwan P; Aydinok Y; Werner O; Govindaraju S; Romen F; Viprakasit V
Haematologica; 2024 May; 109(5):1413-1425. PubMed ID: 37855069
[TBL] [Abstract][Full Text] [Related]
20. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
Taher AT; Cappellini MD; Aydinok Y; Porter JB; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Wang C; Zhu Z; Joaquin V; Uwamahoro MJ; Lai YR
Blood Cells Mol Dis; 2016 Mar; 57():23-9. PubMed ID: 26852651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
